Merck: green light for Welireg in China for VHL disease

(CercleFinance.com) - Merck announces that the National Medical Products Administration (NMPA) in China has approved Welireg (belzutifan) for the treatment of adults with von Hippel-Lindau disease (VHL) presenting with clear cell renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas or pancreatic neuroendocrine tumors (pNET) not requiring immediate surgery.


This approval is based on the results of a Phase 2 clinical trial showing a 49% response rate in patients with VHL-associated RCC.

Positive results were also observed in CNS hemangioblastoma (63%) and pNET (83%).

Merck continues to evaluate Welireg in a clinical program for advanced RCC and other tumor types.

Copyright (c) 2024 CercleFinance.com. All rights reserved.